Feedback
Settings

Settings

Goto Application

1. WO2022164721 - LIPIDS THAT REDUCE LUNG DAMAGE, IMPROVE PULMONARY FUNCTION AND DECREASE PRO-INFLAMMATORY CYTOKINES

Submit observation
PermaLink
Publication Number WO/2022/164721
Publication Date 04.08.2022
International Application No. PCT/US2022/013283
International Filing Date 21.01.2022
IPC
A61K 31/22 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
22of acyclic acids, e.g. pravastatin
A61K 31/683 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 9/127 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
127Liposomes
CPC
A61K 31/683
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
02Inorganic compounds
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
A61K 9/0073
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
007Pulmonary tract; Aromatherapy
0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy;
A61K 9/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
145with organic compounds
Applicants
  • SIGNPATH PHARMA, INC. [US]/[US]
Inventors
  • SORDILLO, Pater, P.
  • ALLAIRE, Andrea
  • BOUCHARD, Annie
  • SALVAIL, Dan
  • LABBE, Sebastien, M.
Agents
  • CHALKER, Daniel, J.
  • FLORES, Edwin, S.
Priority Data
63/143,51129.01.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) LIPIDS THAT REDUCE LUNG DAMAGE, IMPROVE PULMONARY FUNCTION AND DECREASE PRO-INFLAMMATORY CYTOKINES
(FR) LIPIDES QUI RÉDUISENT LES LÉSIONS PULMONAIRES, AMÉLIORENT LA FONCTION PULMONAIRE ET RÉDUISENT LES CYTOKINES PRO-INFLAMMATOIRES
front page image
Abstract
(EN) A method of treating a disease or pathology caused by an increase in levels of inflammatory cytokines comprising providing the subject with a compound of Formula I, (I) wherein, R1 is a C1-C20 branched or unbranched hydrocarbon; R3 is (II); or R4 is H or a pharmaceutically acceptable cation; R5 is a C1-C10 branched or unbranched hydrocarbon or optionally substituted with one or more groups; R6 is a C1-C10 branched or unbranched hydrocarbon or optionally substituted; R7 is a C0-C20 branched or unbranched hydrocarbon; R8 is H or a C0-C20 branched or unbranched hydrocarbon; X is a direct linkage, CH2, O or NH; Y is a direct linkage, CH2, O or NH; and, each stereogenic center is independently R, S or racemic.
(FR) L'invention concerne une méthode de traitement d'une maladie ou d'une pathologie provoquée par une augmentation des taux de cytokines inflammatoires, consistant à administrer au sujet un composé de formule I, (I) dans laquelle R1 est un hydrocarbure ramifié ou non ramifié en C1-C20 ; R3 est (II) ; ou R4 est H ou un cation pharmaceutiquement acceptable ; R5 est un hydrocarbure ramifié ou non ramifié en C1-C10 ou éventuellement substitué par un ou plusieurs groupes ; R6 est un hydrocarbure ramifié ou non ramifié en C1-C10 ou éventuellement substitué ; R7 est un hydrocarbure ramifié ou non ramifié en C0-C20 ; R8 est H ou un hydrocarbure ramifié ou non ramifié en C0-C20 ; X est une liaison directe, CH2, O ou NH ; Y est une liaison directe, CH2, O ou NH ; et chaque centre stéréogénique est indépendamment R, S ou racémique.
Latest bibliographic data on file with the International Bureau
# -